Whole-genome sequencing (WGS) is a genetic testing approach in which genetic information is analyzed across the entire genome using next-generation sequencing (NGS) technology. Unlike targeted tests that analyze preselected regions (so-called gene panels), WGS generates a single, comprehensive dataset covering the entire genome. The resulting data are then evaluated by a clinical geneticist in the context of the specific clinical question—for example, clarifying the cause of health problems, assessing genetic risk within a family, or analyzing genetic factors that influence treatment response. In clinical practice, WGS does not serve as a “one-time answer,” but rather as a foundation for subsequent evaluation. The sequencing itself produces a large dataset, which is computationally processed to identify potentially significant genetic variants. Only then does clinical interpretation take place: variants are assessed in relation to the indication for testing, the patient’s symptoms, family history, and the current state of scientific knowledge. It is important to distinguish between raw data and the clinical conclusion—the practical value arises only once findings are professionally interpreted and further steps are proposed. 

The testing process usually begins with the collection of biological material (most often peripheral blood), from which DNA is isolated. This is followed by a whole-genome sequencing using an NGS platform and computational processing of the sequencing data. During bioinformatic analysis, sequencing data are aligned to a reference genome, relevant genetic variants are identified, and these variants are described and evaluated using specialized databases and current scientific literature. This phase is followed by clinical evaluation, whose purpose is to translate genomic data and detected variants into a clear, medically interpretable result.

One of the key features of WGS is the ability to focus evaluation on a specific clinical area of interest. In practice, this means that interpretation can be conducted as a targeted analysis—for example, focusing on genes and genomic regions associated with cardiovascular or neurological diseases, cancer, reproductive health, or other clinical domains. If necessary, previously generated genomic data can be re-analysed and the scope of evaluation expanded without repeating the laboratory part of the test. This approach is particularly useful when the clinical presentation is unclear, overlaps multiple diagnoses, or evolves over time.

In the diagnosis of rare and genetically heterogeneous diseases, WGS is among the methods that may increase the likelihood of identifying a genetic cause. Meta-analyses of clinical studies in pediatric patients with rare and unresolved genetic disorders indicate that WGS achieves, on average, a higher diagnostic yield than panel sequencing. In practice, this may result in a faster establishment of a diagnosis at the genetic level, more precise targeting of subsequent care, and a reduction in the need for stepwise addition of further genetic tests, which are both time- and cost-intensive. For certain conditions, early identification of the genetic cause can directly influence treatment strategy (for example, the choice of targeted therapy or timing of intervention) and may thus influence the clinical course. 

The clinical utility of WGS extends beyond diagnostics. In preventive genetics, it can identify germline variants associated with an increased risk of specific diseases in certain individuals. The purpose of such findings is not to “predict the future,” but to enable more precise medical management — for example, through individually tailored monitoring, appropriate preventive examinations, or recommendations for testing other family members. Interpretation of such findings requires caution and must be placed within a clinical context, as the degree of risk and the likelihood of disease development may vary between individuals.

Genomic data can also serve as a basis for assessing carrier status of pathogenic variants in couples planning a family. It is particularly valuable in situations where severe disease recurs within a family or when there is suspicion of a genetic cause. In such cases, WGS provides clinically meaningful information for family planning and for clarifying health concerns affecting family members.

A separate and increasingly important application is pharmacogenomic analysis, i.e., the assessment of genetic factors influencing the drug metabolism and effects of certain medications. Because genetic information does not change over time, it can serve as a long-term basis for selecting specific therapies. For certain medications, international guidelines provide recommendations on how genetic findings should guide drug selection or dosing adjustments, with the aim of reducing adverse effects and improving treatment safety and efficacy.

Whole-genome sequencing is best understood as a comprehensive data foundation that can be used for targeted clinical interpretation according to evolving needs. “Data for a lifetime” in this context does not mean a one-time universal conclusion, but rather the possibility of professional and appropriate re-evaluation of genomic information over time: as health circumstances change, new scientific knowledge emerges, and clinical recommendations become more refined. If the entire process is properly established—from high-quality biological sample processing and sequencing data generation to standardized interpretation and clear medical communication—WGS can deliver tangible clinical benefits across diagnostics, prevention, and care management.